GRAIL is trading 4.08% down at $134.00 in pre-market on October 15, with broader risk-off sentiment a possible backdrop; no new company-specific catalyst surfaced. - Hotter-than-expected U.S. inflation fueled rate concerns as tech and global markets weakened. - GRAIL previously reported a favorable FDA advisory-panel vote for Galleri, but that earlier news does not explain this morning’s decline.